Complement Deficiencies: C1 Deficiency and Associated Disorders.- C5b-C9 Deficiency.- Complement C3 Deficiency.- Complement Component C2 Deficiency.- Associated with Atypical Hemolytic Uremic Syndrome.- Complete Deficiency of Complement C4.- Ficolin-3.- Hereditary Deficiency of C1 Inhibitor and Angioedema.- Mannose-Binding Lectin-Associated Serine Protease-2 (MASP-2) Deficiency.- Primary and Secondary CD59 Deficiency.- Properdin Deficiency.- Dysregulation-CD27 Deficiency.- DKC1, Dyskeratosis Congenita/Hoyeraal-Hreidarsson Syndrome.- FAAP24 Deficiency.- PRF1 Deficiency.- STX11 Deficiency.- STXBP2 Deficiency.- TERC Deficiency.- TERT.- UNC13D Deficiency.- XIAP Deficiency.- Defects in Innate Immunity: Anhidrotic Ectodermal Dysplasia with Immunodeficiency (EDA-ID), Autosomal-Dominant.- Anhidrotic Ectodermal Dysplasia with Immunodeficiency (EDA-ID), X-linked.- APOL-1 Variants, Susceptibility and Resistance to Trypanosomiasis.- CARD9 Deficiency.- Chronic Mucocutaneous Candidiasis, ACT1 Deficiency.- Chronic Mucocutaneous Candidiasis, IL-17F Deficiency.- Chronic Mucocutaneous Candidiasis, STAT1 Gain of Function.- Chronic Mucocutaneous Candidiasis: IL-17RA Deficiency.- EVER1 and EVER2 Mutations in Epidermodysplasia Verruciformis.- IRF3 Deficiency.- Isolated Congenital Asplenia (ICA) and Mutations in RPSA.- Predisposition to Severe Viral Infection, MCM4 Deficiency.- Predisposition to Severe Viral Infection, STAT2 Deficiency.- TBK1 Deficiency.- TIR Signaling Pathway Deficiency, HOIL1 Deficiency.- TIR Signaling Pathway Deficiency, IRAK-4 Deficiency.- TIR Signaling Pathway Deficiency, MyD88 Deficiency.- TLR3 Deficiency.- TRAF3 Deficiency.- TRIF Deficiency.- UNC93B1 Deficiency.- Warts, Hypogammaglobulinemia, Infections, Myelokathexis (WHIM) Syndrome.- Combined Immunodeficiencies: B Cell Lymphoma/Leukemia 10 Deficiency.- Caspase Recruitment Domain 11, CARD11.- CD3d, e and z Deficiencies.- CD40 Deficiency, Hyper-IgM Syndrome Type 3 (OMIM # 606843).- CD8 alpha (CD8A) Deficiency.- Cytidine 5-Prime Triphosphate Synthase 1 (CTPS1) Deficiency (OMIM # 615897).- Dedicator of Cytokinesis 2: DOCK2 Deficiency.- DOCK8 Deficiency.- ICOS (Inducible T-Cell Costimulatory) Deficiency (OMIM # 607594).- IKBKB Deficiency.- IL21, Deficiency of.- IL21Receptor, Deficiency of.- ITK Deficiency.- LRBA (Lipopolysaccharide-Responsive and Beige-Like Anchor Protein) Deficiency (OMIM# 614700).- Lymphocyte Specific Protein Tyrosine Kinase, LCK.- MAGT1 Deficiency.- MALT1 Deficiency.- Mammalian sterile 20-like 1 (MST1) deficiency.- MHC Class I, A Deficiency of.- MHC Class II, Deficiency of.- NF-kappa B-Inducing Kinase (NIK).- Omenn Deficiency.- OX40 Deficiency.- Ras Homolog Family Member H (RHOH) Deficiency.- TCR- alpha Deficiency.- X-Linked Hyper-IgM Syndrome: CD40Ligand Deficiency (OMIM # 308230).- ZAP70 Deficiency (OMIM # 176947).- Combined Immunodeficiencies with Associated or Syndromic Features: ADA and PNP Deficiency.- Telangiectasia (ATM).- Ataxia-Telangiectasia-Like Disorder (ATLD).- Autosomal Dominant Anhidrotic Ectodermal Dysplasia with Immunodeficiency (AD-EDA-ID).- Autosomal Dominant Hyper IgE Syndrome.- Bloom Syndrome.- Calcium Channel Defects (STIM1 and ORAI1).- Cartilage Hair Hypoplasia (RMRP).- CHARGE Syndrome (CHD7, SEMA3E).- Clinical Presentation of Polymerase E1 (POLE1) and Polymerase E2 (POLE2) Deficiencies.- Comel-Netherton Syndrome (SPINK5).- Defects in B12 and Folate Metabolism (TCN2, SLC46A1 (PCFT Deficiency), MTHFD1).- DiGeorge Anomaly (del22q11).- Down Syndrome.- Hepatic Veno-occlusive Disease with Immunodeficiency (VODI).- IKAROS (IKZF1) Deficiency.- Immunodeficiency with Multiple Intestinal Atresias (TTC7A).- Immunodeficiency, Centromeric Instability, and Facial Dysmorphism (ICF Syndrome) (ICF1-DNMT3B, ICF-2 ZBTB24).- Jacobsen Syndrome.- Kabuki Syndrome.- LUBAC Deficiencies.- MCM4 Deficiency.- Nijmegen Breakage Syndrome (NBS1).- PGM3-deficiency.- PMS2 Deficiency.- RIDDLE Syndrome (RNF168
About the Author:

Professor Ian Mackay is an Honorary Professional Research Fellow of Monash University, Australia, and member of the Department of Biochemistry and Molecular Biology.

In a career spanning over six decades, with over 700 publications, Professor Mackay has gained international recognition as a pioneer in the area of autoimmunity; with his research contributing to the development of immunosuppressive treatment for autoimmune diseases.

In recognition of his service to medical research, Prof. Mackay was included in the 1981 Australia Day Honours list and was appointed as a Member of the Order of Australia. In 2001 he was awarded the Centenary Medal for service to Australian society and science in biochemistry and molecular biology.

Dr. Rose is the Director of Center for Autoimmune Disease Research and a Professor in the Department of Pathology (with joint appointment in Department of Medicine), the Johns Hopkins University School of Medicine and a Professor in the W. Henry Feinstone Department of Molecular Microbiology and Immunology, the Johns Hopkins University Bloomberg School of Public Health. Dr. Rose also served as the Chairman of the Autoimmune Diseases Coordinating Committee of the National Institutes of Health and a principal advisor to the former U.S. NIH Director Dr. Elias A. Zerhouni. He was the Chairman of the W. Henry Feinstone Department of Molecular Microbiology and Immunology of the Johns Hopkins University Bloomberg School of Public Health for more than a decade.

Dr. Rose's pioneering studies on autoimmune thyroiditis and myocarditis helped to initiate the modern era of research on autoimmune diseases. Dr. Rose and his colleagues have continued to contribute to our understanding of autoimmunity, including the first demonstration of the genetic factors responsible for predisposition to autoimmune disease in animals and more recent investigations on the influence of infection and environmental agents in the initiation of

Dr. Rose is the co-author of the textbook The Autoimmune Diseases (now 3rd edition) and former Editor-in-Chief of Clinical Immunology. He is currently the Editor-in-Chief of The Year in Immunology.